Ann Rheum Dis 70:389-390 doi:10.1136/ard.2009.127787
  • Letters

Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis

  1. Willem F Lems1,3
  1. 1Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
  2. 2Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands
  3. 3Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherland
  1. Correspondence to Danielle A Eekman, Department of Rheumatology, VU University Medical Center, de Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands; d.eekman{at}
  • Accepted 5 April 2010
  • Published Online First 6 May 2010

Osteoporosis is a well-known complication of rheumatoid arthritis (RA), related to disease activity, steroid use and immobility.1,,6

In a 1-year observational study it has been suggested that infliximab can have a positive effect on bone mineral density (BMD) in patients with RA.6 In the present study, patients with RA who had been treated with infliximab for 2 years and more in the Slotervaart Hospital or the VU University Medical Center were included if BMD measurements at baseline and at 2-year intervals had been performed. Patients fulfilled the American College of Rheumatology 1987 criteria and had a disease activity score in 28 joints greater than 3.2 at baseline. Infliximab (3 mg/kg) was given at 0, 2, 6 and 14 weeks and thereafter every 8 weeks.

BMD measurements of the spine (L1–L4) …

Free sample This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article